Stock AnalizNurix Therapeutics, Inc. NRIX
Biotechnology: Pharmaceutical Preparations · IPO 2020 · data as of November 13, 2026
Nurix Therapeutics, Inc. (NRIX) is a healthcare company listed in the US with a market value of about $1.7B. In the twelve months to August 31, 2026 it had revenue of $702M and net income of $295M, a net margin of 42.0%.
Its overall Stock Analiz score is 2.4 out of 5 (weak). The strongest part is value (4/5); the weakest is shareholder returns (0/5).
Key numbers: a P/E of 6.1, a price to free cash flow of 4.6, 5-year revenue growth of 36% a year, a 5-year average ROIC of -44%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 35% above the current price.
Score: 2.4 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
Checks not passed
- PEG below 1.5
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
- Profitable 5 years in a row
- ROE above 15%
- Interest covered more than 5 times
Valuation
Growth and quality
Financials, last 7 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $702M | $84M | $55M | $77M | $39M | $30M | $18M | $31M |
| Net income | $295M | -$264M | -$194M | -$144M | -$180M | -$117M | -$43M | -$22M |
| Free cash flow | $370M | -$263M | -$182M | -$90M | -$172M | -$90M | -$5M | -$1M |
| EPS (diluted) | $2.54 | $-3.05 | $-2.88 | $-2.65 | $-3.71 | $-2.73 | $-2.76 | $-6.59 |
| Net margin | 42.0% | -314.9% | -354.9% | -187.0% | -466.9% | -393.9% | -242.7% | -69.7% |
| ROIC | — | -38.0% | -30.3% | -67.1% | -58.2% | -26.2% | -15.2% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 14 analysts is $33.50, 116% above the current price; targets range from $20.00 to $41.00; the consensus rating is “Strong buy”; expected EPS is $3.02 for the fiscal year ending November 30, 2026.
Frequently asked questions
What is Nurix Therapeutics’s P/E ratio?
About 6.1, based on the last twelve months of diluted earnings per share (forward P/E about 55.2).
Is Nurix Therapeutics stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 35% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Nurix Therapeutics pay a dividend?
Not currently.
Is Nurix Therapeutics a good stock to buy?
We do not give buy or sell advice. Nurix Therapeutics scores 2.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.